Zai Lab Ltd - Company Profile
Powered by 
All the sales intelligence you need on Zai Lab Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Zai Lab Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Zai Lab Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that focuses on the research, development, and commercialization of transformative medicines in the fields of oncology, immunology, neuroscience, and infectious diseases. It’s pipeline products include tisotumab vedotin which treats cervical cancer; zocilurtatug pelitecan targets extensive-stage small-cell lung cancer and neuroendocrine carcinomas; ZL-6201 for sarcoma and CAF+ solid tumor; ZL-1311 targets GI tumors; efgartigimod for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, myositis, seronegative gMG, ocular MG, sjogren’s disease and gastroesophageal reflux disease; among others. The company commercializes its products under the brand names Optune, Qinlock, ZEJULA, NUZYRA and VYVGART. It operates in Hong Kong, Taiwan, China, Australia and the US, among others. Zai Lab is headquartered in Shanghai, China.
Headquarters
China
Address
4th Floor Building 1, 4560 Jinke Road, Shanghai, 201203
Website
www.zailaboratory.com
Telephone
86 21 61632588
No of Employees
1,784
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZLAB (NASD)
Revenue (2024)
$460.2M
15.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
31.7%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
40.8%
(2024 vs 2023)
* As of and is in US$
Zai Lab Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tisotumab Vedotin: Cervical Cancer | Optune |
| Zocilurtatug Pelitecan: | Qinlock |
| Extensive-Stage Small-Cell Lung Cancer | NUZYRA |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company received approval from the China’s National Medical Products Administration for TIVDAK (tisotumab vedotin for injection) to treat adult patients with cervical cancer with disease progression on or after chemotherapy. |
| 2026 | Regulatory Approval | In June, the company received a grant designation from the European Medicines Agency for zocilurtatug pelitecan, a first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate, for the treatment of pulmonary neuroendocrine carcinomas. |
| 2026 | Contracts/Agreements | In April, the company signed a partnership with Amgen Inc to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate, zocilurtatug pelitecan in combination with Amgen’s IMDELLTRA |
Competitor Comparison
| Key Parameters | Zai Lab Ltd | Innovent Biologics Inc | Livzon Pharmaceutical Group Inc | Bio-Thera Solutions Ltd | Antengene Corp Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Suzhou | Zhuhai | Guangzhou | Shanghai |
| State/Province | Shanghai | Jiangsu | Guangdong | Guangdong | Shanghai |
| No. of Employees | 1,784 | 7,502 | 8,878 | 1,426 | 129 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samantha Du | Chief Executive Officer; Chairman | Executive Board | 2014 | 61 |
| Yajing Chen, PhD | Chief Financial Officer | Senior Management | 2023 | 58 |
| F. Ty Edmondson | Chief Legal Officer; Secretary | Senior Management | 2020 | 60 |
| Rafael G. Amado | Head - Global Research and Development; President | Senior Management | 2022 | 62 |
| Christine Chiou | Senior Vice President; Head - Investor Relations | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer